Cyclopharm Ltd
Cyclopharm Limited manufacture and sells medical equipment and radiopharmaceuticals in the Asia Pacific, Europe, Canada, the United States, and internationally. The company operates Technegas which offers diagnostic equipment and consumables used by physicians in the detection of pulmonary embolism and other respiratory conditions. It is also involved in the research and development; and distribu… Read more
Cyclopharm Ltd (CYC) - Total Assets
Latest total assets as of June 2025: AU$55.91 Million AUD
Based on the latest financial reports, Cyclopharm Ltd (CYC) holds total assets worth AU$55.91 Million AUD as of June 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Cyclopharm Ltd - Total Assets Trend (2005–2024)
This chart illustrates how Cyclopharm Ltd’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Cyclopharm Ltd - Asset Composition Analysis
Current Asset Composition (December 2024)
Cyclopharm Ltd's total assets of AU$55.91 Million consist of 68.2% current assets and 31.8% non-current assets.
| Asset Category | Amount (AUD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | AU$0.00 | 33.1% |
| Accounts Receivable | AU$7.50 Million | 12.1% |
| Inventory | AU$13.25 Million | 21.3% |
| Property, Plant & Equipment | AU$13.10 Million | 21.1% |
| Intangible Assets | AU$4.97 Million | 8.0% |
| Goodwill | AU$929.11K | 1.5% |
Asset Composition Trend (2005–2024)
This chart illustrates how Cyclopharm Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Cyclopharm Ltd's current assets represent 68.2% of total assets in 2024, an increase from 61.2% in 2005.
- Cash Position: Cash and equivalents constituted 33.1% of total assets in 2024, down from 41.2% in 2005.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 8.0% of total assets, a decrease from 31.0% in 2005.
- Asset Diversification: The largest asset category is inventory at 21.3% of total assets.
Cyclopharm Ltd Competitors by Total Assets
Key competitors of Cyclopharm Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
C.Q. Pharmaceutical Holding Co Ltd
SHE:000950
|
China | CN¥67.71 Billion |
|
Shenzhen Glory Medical Co Ltd
SHE:002551
|
China | CN¥3.56 Billion |
|
Shandong Realcan Pharmaceutical Co Ltd
SHE:002589
|
China | CN¥15.33 Billion |
|
Hanmi Science
KO:008930
|
Korea | ₩1.45 Trillion |
|
BCM Alliance Bhd
KLSE:0187
|
Malaysia | RM147.86 Million |
|
Qingdao Baheal Medical INC.
SHE:301015
|
China | CN¥7.59 Billion |
|
Excelsior Medical Co Ltd
TW:4104
|
Taiwan | NT$18.80 Billion |
|
CHC Healthcare Group
TW:4164
|
Taiwan | NT$14.83 Billion |
Cyclopharm Ltd - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Moderate asset utilization - Cyclopharm Ltd generates 0.44x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Cyclopharm Ltd is currently not profitable relative to its asset base.
Cyclopharm Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 3.19 | 4.38 | 2.76 |
| Quick Ratio | 1.94 | 3.42 | 2.09 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | AU$24.90 Million | AU$ 36.35 Million | AU$ 9.95 Million |
Cyclopharm Ltd - Advanced Valuation Insights
This section examines the relationship between Cyclopharm Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.77 |
| Latest Market Cap to Assets Ratio | 0.39 |
| Asset Growth Rate (YoY) | 35.3% |
| Total Assets | AU$62.13 Million |
| Market Capitalization | $24.34 Million USD |
Valuation Analysis
Below Book Valuation: The market values Cyclopharm Ltd's assets below their book value (0.39 x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Cyclopharm Ltd's assets grew by 35.3% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Cyclopharm Ltd (2005–2024)
The table below shows the annual total assets of Cyclopharm Ltd from 2005 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | AU$62.13 Million | +35.31% |
| 2023-12-31 | AU$45.91 Million | -7.32% |
| 2022-12-31 | AU$49.54 Million | -11.12% |
| 2021-12-31 | AU$55.74 Million | +97.14% |
| 2020-12-31 | AU$28.28 Million | -13.08% |
| 2019-12-31 | AU$32.53 Million | +38.20% |
| 2018-12-31 | AU$23.54 Million | +0.68% |
| 2017-12-31 | AU$23.38 Million | +42.41% |
| 2016-12-31 | AU$16.41 Million | -0.76% |
| 2015-12-31 | AU$16.54 Million | +50.90% |
| 2014-12-31 | AU$10.96 Million | +21.65% |
| 2013-12-31 | AU$9.01 Million | -58.39% |
| 2012-12-31 | AU$21.66 Million | +1.71% |
| 2011-12-31 | AU$21.29 Million | -3.83% |
| 2010-12-31 | AU$22.14 Million | +12.71% |
| 2009-12-31 | AU$19.64 Million | +5.73% |
| 2008-12-31 | AU$18.58 Million | +69.25% |
| 2007-12-31 | AU$10.98 Million | +21.15% |
| 2006-12-31 | AU$9.06 Million | -56.84% |
| 2005-12-31 | AU$20.99 Million | -- |